Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. NAVB, GNCA, PXMD, ARDS, and GNCAQ

Should you buy Comera Life Sciences stock or one of its competitors? Comera Life Sciences's main competitors and comparable companies include Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Comera Life Sciences Neutral

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Comera Life Sciences has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Comera Life Sciences N/A N/A N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

Comera Life Sciences (NASDAQ:CMRA) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
PaxMedica Neutral

Comera Life Sciences has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

4.9% of PaxMedica shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Aridis Pharmaceuticals Neutral

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals. Comera Life Sciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Comera Life Sciences has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.62, indicating that its share price is 4,862% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Genocea Biosciences has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats Genocea Biosciences on 2 of the 3 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3K$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / SalesN/A743.50592.5787.62
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net Income-$18M$2.77B$3.45B$347.60M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
-28.6%		N/AN/A$6KN/AN/A2
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/A$5KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel